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Amiodarone  chlorhydrate  is  a  diiodated  benzofuran  derivative,  and  it  is  used  to  treat  cardiac  rhythm  abnormalities. 
Hepatotoxicity  is  a  relatively  uncommon  side  effect  of  amiodarone,  and  symptomatic  hepatic  dysfunction  occurs  in 
fewer  than  1%  of  the  patients  taking  amiodarone.  Cirrhosis  is  a  rare  complication  that's  been  confirmed  in  12  cases. 
Peripheral  neuropathy  occurs  in  10%  of  patients  taking  aminodarone.  We  report  here  on  an  unusual  case  of 
amiodarone-induced  hepatotoxicity  and  peripheral  neurotoxicity.  A  75  year  old  man  with  normal  liver  function  was  given 
amiodarone  for  treating  his  atrial  fibrillation  and  heart  failure.  He  developed  nausea,  vomiting,  muscle  weakness  and 
wasting  after  17.8  months  therapy  with  amiodarone  (400  mg  orally  once  per  day).  Liver  biopsy  showed  the  presence 
of  foam  cells  in  the  hepatic  sinusoids  and  Mallory  bodies  in  the  periportal  hepatocytes  on  light  microscopy.  Sural  nerve 
biopsy  showed  demyelination,  and  nerve  conduction  studies  showed  mixed  sensorimotor  polyneuropathy.  These 
observations  show  the  necessity  of  monitoring  the  hepatic  function  and  conducting  neurologic  examination  of  the 
patients  treated  with  amiodarone.
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INTRODUCTION
Amiodarone  is  an  iodine-rich  drug  that  is  a  highly  effective 
and  widely  used  as  an  antiarrhythmic  agent  for  the  treatment  of 
symptomatic  supraventricular  and  ventricular  tachyarrhythmias. 
Amiodarone  is  associated  with  many  adverse  effects  that 
involve  different  organs.  Although  these  side  effects  are 
generally  mild,  10～15%  of  patients  require  withdrawal  of  the 
drug  as  a  result  of  toxicity.  The  most  prominent  adverse  effects 
during  long-term  therapy  include  thyroid  dysfunction,  corneal 
microdeposits  and  pulmonary  and  hepatic  toxicity
1).  Transient 
rises  in  hepatic  enzyme  activity  have  been  reported  in  40%  of 
the  patient  who  received  the  antiarrhythmic  agent  amiodarone
2). 
Asymptomatic  elevation  of  serum  aminotransferases  occurs  in 
25%  of  those  patients  who  are  treated  with  aniodarone. 
However,  the  prevalence  of  severe  liver  injury  has  been 
estimated  at  only  1%  to  3%
3).  Micronodular  cirrhosis  that  was 
clearly  due  to  amiodarone  therapy  has  been  confirmed  in  12 
cases
4).  Muscle  weakness  and  peripheral  neuropathy  have  also 
been  reported  in  10%  of  the  patients  who  were  administered  the 
anti-arrhythmic  agent  amiodarone
5,  6).  We  describe  here  a  case 
of  amiodarone-induced  hepatitis  and  neuropathy  after  treatment 
with  400  mg  of  oral  amiodarone  for  17.8  months. 
CASE REPORT
A  75  year  old  man  was  hospitalized  in  December  2005  due 
to  nausea,  vomiting  and  difficulty  in  walking  and  raising  his  legs 
to  walk  up  steps  for  the  previous  three  months.  Since  July  2004, 
the  patient  had  been  given  amiodarone  400  mg  daily  for  treating 
his  atrial  fibrillation  and  heart  failure.  His  heart  rhythm  was The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  3,  September  2007 226
Figure  1.  Pre-enhanced  computed  tomogram  of  the  abdomen 
showing  diffuse  high  attenuation  of  the  liver  parenchyma. 
Figure 2. Liver biopsy showing clusters of foam cells in the hepatic 
sinusoidal  spaces  and  micro-&  and  macrovesicular  fatty  change 
(H&E,  ×200).
Figure  3.  Periportal liver cells contain Mallory bodies (H&E, ×200).
converted  to  sinus  rhythm  after  amiodarone  therapy.
He  had  a  history  of  pulmonary  tuberculosis,  which  was 
treated  with  anti-tuberculosis  drugs  30  years  prior  to  this 
hospitalization.  He  had  drank  40  g  of  alcohol  per  day  for  20 
years  before  his  abstinence  from  drinking  4  months  ago.  His 
other  medications  at  admission  were  carvediol  12.5  mg  twice 
per  day,  diltiazem  30  mg  twice  per  day  and  triflusal  300  mg 
once  per  day.  He  denied  the  use  of  other  hepatotoxic  drugs  or 
toxins.  His  liver  function  before  amiodarone  therapy  was  normal. 
He  denied  any  current  cardiovascular  or  pulmonary  symptoms. 
The  vital  signs  were  normal.  His  body  weight  and  body  mass 
index  were  50  kg  and  17.7,  respectively.  Neurologic  examination 
showed  striking  bilateral  weakness  of  the  hip  and  knee  flexors 
and  extensors.  The  weakness  became  more  diffuse,  affecting 
the  proximal  muscles  more  than  the  distal  muscles.  There 
weren't  a  fluid  ware,  shifting  dullness  and  pretibial  pitting  edema. 
The  other  physical  examination  was  also  nonspecitic.  The 
laboratory  findings  on  the  admission  were  as  follows:  serum 
aspartate  aminotransferase  123  IU/L;  serum  alanine 
aminotransferase  146  IU/L;  serum  albumin  2.5  g/dL;  serum 
bilirubin  0.8  mg/dL;  alkaline  phosphatase  99  IU/L;platelets 
212,000  cells/uL;  blood  hemoglobin  13.1  g/dL;  negative  results  of 
tests  for  hepatitis  B  surface  antigen,  hepatitis  A  antibody, 
hepatitis  C  antibody  and  the  VDRL  test.  The  serum  fasting 
transferrin  saturation  level  was  normal.  The  serum  antinuclear 
antibody  was  positive,  but  other  autoantibodies,  including 
anti-dsDNA,  anti-Sm  and  anti-Ro,  anti-La  antibody  were 
negative.  Also,  the  anti-smooth  muscle  and  anti-mitochondrial 
antibodies  were  negative.  The  thyroid  function  test  and  urine 
analysis  were  within  the  normal  limits.  A  pre-enhanced 
computed  tomogram  of  the  abdomen  showed  diffuse  high 
attenuation  of  the  liver  parenchyma  (Figure  1).  Liver  biopsy 
showed  microvesicular  steatosis,  foam  cells  in  the  hepatic 
sinusoids  and  mallory  bodies  in  the  periportal  hepatocytes,  and 
also  features  of  chronic  hepatitis  (mild  lobular  activity,  grading 
score  2;  minimal  porto-peripheral  activity,  grading  score  1;  portal 
fibrosis,  staging  score  1)  on  the  light  microscopy  (Figure  2-4). 
With  electron  microscopy,  the  hepatocytes  showed  pleomorphic 
mitochondria  that  had  crystalloid  inclusions  and  focal  concentric 
membranous  arrays,  which  suggested  membrane-bound 
lysosomal  structures.  Both  findings  strongly  suggested 
amiodarone-induced  hepatotoxicity. 
Nerve  conduction  studies  and  electromyography  were 
performed  after  admission.  They  suggested  sensorimotor  poly-
neuropathy  with  both  axonal  degeneration  and  demyelination 
(Table  1,  2).  The  neurophysiologic  investigations  showed 
slowing  of  the  sensory  and  motor  conduction  velocities,  delay  of 
the  distal  latencies  and  F-wave  latencies  of  the  motor  nerves, 
and  delay  of  the  H-reflex  latency  of  the  tibial  nerve.  The Hyun  Mo  Kang,  et  al  :  Amiodarone-induced  Hepatitis  and  Polyneuropathy 227
 
Figure 4. Liver  biopsy  showed mild lobular activity (A,  H&E, ×100),  minimal  periportal  activity and  fibrous portal expansion (B,  Masson's 
Trichrome  stain,  ×200). 
Motor  nerve Normal  values
Peroneal  nerve
Post.  tibial  nerve
Ulnar  nerve
Median  nerve
MCV
DL
F.  Lat
Amp
MCV
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F.  Lat
Amp
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DL
F.  Lat
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m/s
ms
ms
mV
m/s
ms
ms
mV
m/s
ms
ms
mV
m/s
ms
Ms
mV
32
5.1
63.6
1.0
41
5.4
59.7
3.0
42
3.5
33.7
7.4
49
3.8
31.4
12.4
41.65
4.78
50.03
5.0
40.63
5.11
52.02
5.0
50.61
2.51
29.04
5.0
49.96
3.60
28.85
5.0
MCV,  motor  conduction  velocity;  DL,  distal  latency;  F.  Lat,  F-wave  latency;  Amp,  potential  amplitude
Table  1.  Motor  nerve  conduction  studies
histologic  findings  from  the  sural  nerve  showed  focal 
demyelination  (Figure  5).  Amiodarone  was  withdrawan  and  the 
patients  experienced  temporary  clinical  improvement.  The  liver 
enzyme  activity  on  day  3  after  amiodarone  withdrawal  was  as 
follows:  serum  aspartate  aminotransferase  31  IU/L;  serum 
alanine  aminotransferase  27  IU/L.  The  interruption  of  amiodarone 
therapy  improved  the  neuropathy.  The  patient  fully  recovered 
from  the  muscle  weakness  and  nausea  at  1  month  after  the 
cessation  of  amiodarone. 
DISCUSSION
Amiodarone  is  lipophilic,  and  so  it  accumulates  in  lipid-laden 
organs  such  as  the  liver.  Amiodarone  and  its  major  metabolite, 
N-desethylamiodarone,  accumulate  in  the  lysosomes  of  the 
hepatocytes,  Kupffer  cells  and  bile  duct  epithelium.  The  cationic 
amphophilic  amiodarone  molecule  binds  to  phospholipids  in  the 
lysosomes  and  forms  a  nondigestable  complex
7,  8).  This  causes 
accumulation  of  phospholipids  in  lysosomes,  resulting  in 
secondary  phospholipidosis.  The  presence  of  foam  cells  in  the 
hepatic  sinusoids  on  light  microscopy  and  the  membrane-bound 
lysosomal  structures  (lamellated  inclusions)  or  the  crystalloid 
inclusions  on  electron  microscopy  suggest  phospholipidosis
3, 7, 9). 
These  finding,  such  as  foam  cells  in  the  hepatic  sinusoids  and 
crystalloid  inclusions  were  also  seen  on  our  studies.  It  is 
uncertain  whether  hepatocellular  injury  is  due  to  pho-
spholipidosis
6)  or  the  metabolic  effects  of  amiodarone  and  its 
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Normal  values
Medianl  nerve
Ulnar  nerve
Sural  nerve
SCV
S.pot.ampl
SCV
S.pot.ampl
SCV
S.pot.ampl
m/s
uV
m/s
uV
m/s
uV
37
10
36
9
No  potential
49.39
10
47.46
8
34.68
6
H-reflex  on  tibial  nerve Latency ms 40.8 30.5
SCV,  sensory  conduction  velocity;  DL,  distal  latency;  F.  Lat,  F-wave  latency;  S.pot.ampl,  sensory  potential  amplitude
Table  2.  Sensory  nerve  conduction  studies  and  the  H-reflex  study
Figure 5. The sural nerve biopsy shown in longitudinal section with 
light microscopy consists of a single fascicle that is not invested by 
the  perineurium  (H&E,  ×200).
metabolites
3, 9).  Yet  the  accumulation  of  lamellated  inclusion 
bodies  suggests  a  drug-induced  disturbance  of  both  lipid 
metabolism  and  lysosomal  function
6).  Rheumatic  diseases  were 
excluded  because  there  were  no  abnormal  clinical  findings  or 
autoimmune  antibodies  except  for  serum  antinuclear  antibody. 
Peripheral  neuropathy  associated  with  amiodarone  was  first 
reported  by  Kaeser  in  1974
10).  Three  types  of  neuropathy  have 
been  reported,  that  is,  axonal  by  Meier  et  al
11),  demyelinating  by 
Kaeser  et  al
12),  and  mixed  by  Dudognon  et  al
13).  Pellissier  et  al 
described  that  the  neuropathy  is  of  a  sensorimotor  type
14).  In   
that  study,  the  daily  dose  of  amiodarone  until  the  onset  of 
neuropathy  was  50～1,800  mg,  and  the  treatment  duration  was 
1～168  months
14);  there  was  no  correlation  between  neuropathy 
and  the  daily  dose,  the  total  dose  or  treatment  duration.  These 
discrepancies  of  the  dose  and  treatment  duration  may  suggest 
interindividual  variability  of  amiodarone  metabolism
14).  In  our 
current  case,  leg  weakness  occurred  14  months  after  starting 
medication  with  a  daily  dose  of  400  mg  amiodarone,  and 
walking  difficulty  happened  after  16  months.  Examination  of  the 
sural  nerves  showed  characteristic  amiodarone-induced 
lamellated  inclusions  in  many  cell  types.  These  inclusions  are 
known  to  be  lysosomal  in  origin,  and  they  are  a  characteristic 
finding  of  amiodarone-induced  neuropathy
15).  The  peripheral 
neuropathy  is  generally  resolved  within  3  days  to  3  months  of 
discontinuing  amiodarone
16).  In  our  case,  the  patient's  muscle 
weakness  improved  after  2  weeks  and  ambulation  was  possible 
at  1  month  after  the  cessation  of  taking  amiodarone.  Even 
though  we  did  not  perform  an  electron  microscopic  exam  on  the 
sural  nerve,  we  consider  the  neurologic  findings  of  our  patient  to 
be  amiodarone-induced  neuropathy  for  many  reasons.  Not  only 
because  of  the  test  results  such  as  the  mixed  sensorimotor 
polyneuropathy  findings  on  nerve  conduction  velocity  studies 
and  electromyography,  and  the  demyelination  findings  on  the 
sural  nerve  biopsy,  but  also  the  clinical  findings  such  as  muscle 
weakness  and  the  improvement  after  cessation  of  amiodarone 
are  enough  to  make  the  correct  diagnosis.  That  the  patients 
had  no  other  definite  cause  for  neuropathy  also  supports  our 
diagnosis.  Careful  questioning  of  past  drug  exposure  is  essential 
for  any  patient  with  altered  biochemical  liver  tests  and 
neurologic  symptoms.  We  suggest  that  amiodarone  should  be 
withdrawn  if  a  patient  shows  neurologic  symptoms  or  if  the  liver 
function  test  results  are  abnormal.  By  doing  so,  it  is  possible  to 
avoid  unnecessary,  costly  diagnostic  evaluation  and  severe 
toxicity.
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